Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II HepaStem dose-regimen study in acute-on-chronic liver failure
2016-001177-32Phase 2Completed
- Sponsor
- Promethera Therapeutics
- Start
- Mar 2016
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2 trial of hepastem in acute-on-chronic liver failure (ACLF), Cirrhosis and chronic liver disease (CLD) (2 arms), sponsored by Promethera Therapeutics. Primary endpoint: Safety assessment. Started Mar 2016; status: completed.
02
Drugs
hepastem
03
Conditions
acute-on-chronic liver failure (ACLF)Cirrhosischronic liver disease (CLD)
Beyond the preview
Go deeper on 2016-001177-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001177-32.